Safely and well invested

Values & Performance of HAEMATO AG

Have you invested in HAEMATO AG or are you interested in the company's performance as a capital market participant? Here you will find all the important information about us and our activities: Current financial reports, key figures and our financial calendar.

Directly to the share price

€ 285 mio. sales in 2021

€ 1.00 per share dividend paid in 2021

635,000 packages sold annually

31 % sales CAGR since 2007

More than 7,000 customers

Investor News

HAEMATO AG announces figures for the first quarter of 2022. According to these figures, the Group's consolidated revenue fell to EUR 54.6 million in the first quarter (previous year: EUR 73.9 million). EBITDA fell from EUR 2.8 million in the same quarter of the previous year to EUR 2.3 million. EBIT amounted to EUR 2.0 million in the first quarter of 2022 (previous year: EUR 2.4 million). The EBITDA margin increased from 3.8% (same quarter of the previous year) to 4.2%. The EBIT margin rose from 3.3% in the previous year to 3.6%. This also includes certain follow-up costs for the restructuring of the group.

Rating & Research

First Berlin Equity Research

Buy: 43.00 €

Warburg Research

Buy: 33.00 €

Aktienkurs

Zum Aktienchart

Safely and well advised

Reports

Get an overview of the status and development of HAEMATO AG. Here you will find information about the group as well as the developments of the past years.

Read reports

News

We would like to inform you about the current business development of HAEMATO AG as well as about our investor relations activities.

To the news archive

Investor News

Berlin, May 3, 2022 - At today's balance sheet meeting, the annual financial statements 2021 of HAEMATO AG, which were issued with an unqualified audit certificate, were adopted. The preliminary figures were confirmed. The Executive Board and Supervisory Board will propose a dividend of EUR 1.10 per dividend-bearing share to the Annual General …

Investor News

Renewed increase in sales and strong rise in earnings after disproportionate growth of the new Lifestyle and Aesthetics business unit. HAEMATO remains on course for growth: according to preliminary IFRS financial statements, consolidated revenue in the 2021 financial year rose again by around 20% to EUR 285.0 million, after revenue growth of a good …

Investor News

In its meeting today, the Supervisory Board of HAEMATO AG appointed Mr. Attila Strauss to the Executive Board of HAEMATO AG with effect from 01.04.2022. Mr. Attila Strauss has already been working as Chief Operating Officer at HAEMATO PHARM GmbH since 01.05.2021 and has also been Managing Director of the company since 01.10.2021.

Upcoming events

HAEMATO AG annual general meeting

Annual General Meeting

interim report

Interim Report 2022

Preliminary Results

Q3 Results 2022

For investors

Do you have any further questions about the group? Our investor relations team is happy to help you..

Contact us